Prosecution Insights
Last updated: October 02, 2026
Application No. 17/907,645

PREPARATION FOR USE AS ANTIOXIDANT

Non-Final OA §112
Filed
Sep 28, 2022
Priority
Apr 01, 2020 — EU 20167501.4 +1 more
Examiner
CHEN, CATHERYNE
Art Unit
1655
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Evonik Operations GmbH
OA Round
3 (Non-Final)
37%
Grant Probability
At Risk
3-4
OA Rounds
2m
Est. Remaining
55%
With Interview

Examiner Intelligence

Grants only 37% of cases
37%
Career Allowance Rate
296 granted / 791 resolved
-22.6% vs TC avg
Strong +18% interview lift
Without
With
+18.0%
Interview Lift
resolved cases with interview
Typical timeline
4y 3m
Avg Prosecution
56 currently pending
Career history
841
Total Applications
across all art units

Statute-Specific Performance

§101
14.3%
-25.7% vs TC avg
§103
41.3%
+1.3% vs TC avg
§102
18.4%
-21.6% vs TC avg
§112
19.4%
-20.6% vs TC avg
Black line = Tech Center average estimate • Based on career data from 791 resolved cases

Office Action

§112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 4/6/2026 has been entered. Claims 1, 7, and 24-38 are pending. Claims 1, 24, 26-27, 29, 31, 33, 35, and 37 are examined on the merits. Claims 7, 25, 28, 30, 32, 34, 36 and 38 are withdrawn. The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action. Any rejection not reiterated below are hereby withdrawn. Response to Amendment Election/Restrictions Claims 7, 25, 28, 30, 32, 34, 36 and 38 are withdrawn from further consideration pursuant to 37 CFR 1.142(b), as being drawn to a nonelected group and species, there being no allowable generic or linking claim. Applicant timely traversed the restriction (election) requirement in the reply filed on Jan. 23, 2025. Applicant's election with traverse of Group I (Claims 1-5, 7-10), the species cyanidin-3-glucoside, lysine, bilberries in the reply filed on Jan. 23, 2025 is acknowledged. The traversal is on the ground(s) that there is no burden to search all the species and groups. This is not found persuasive because a search of one group is not coextensive with the search of the other groups. Thus, it would be burdensome to search the entire claims. The requirement is still deemed proper and is therefore made FINAL. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 1, 24, 26-27, 29, 31, 33, 35, and 37 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 1, the terms EPA and DHA as polysaturated fatty acid component in a range of from 40 to 65 wt% are indefinite. It is not clear what amounts of the substance need to be present in order for the compositions to be considered “in a range of from 40 to 65 wt%” in these compounds. Is it the whole omega-3 lysine complex or just the EPA and DHA? What is the range? Please specify. Conclusion No claim is allowed. Contact Information Any inquiry concerning this communication or earlier communications from the examiner should be directed to CATHERYNE CHEN whose telephone number is (571)272-9947. The examiner can normally be reached on Monday-Friday 9-5:30 PM. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice . If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Anand U Desai can be reached on 571-272-0947. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. Catheryne Chen Examiner Art Unit 1655 /ANAND U DESAI/Supervisory Patent Examiner, Art Unit 1655
Read full office action

Prosecution Timeline

Show 1 earlier event
May 27, 2025
Non-Final Rejection mailed — §112
Aug 27, 2025
Response Filed
Jan 06, 2026
Final Rejection mailed — §112
Mar 30, 2026
Examiner Interview Summary
Mar 30, 2026
Applicant Interview (Telephonic)
Apr 06, 2026
Request for Continued Examination
Apr 07, 2026
Response after Non-Final Action
Jul 27, 2026
Non-Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12741000
TRADITIONAL CHINESE MEDICINE COMPOSITION FOR TREATING PSORIASIS, PREPARATION METHOD THEREFOR AND USE THEREOF
4y 4m to grant Granted Sep 22, 2026
Patent 12697564
Dephosphorylation-controlled extraction of phosphorylatable psychoactive alkaloids
2y 10m to grant Granted Aug 04, 2026
Patent 12673114
COMPOSITION FOR PREVENTING OR TREATING CANCER, CONTAINING IL-2 SURFACE EXPRESSION-EXTRACELLULAR VESICLES AS ACTIVE INGREDIENT
4y 6m to grant Granted Jul 07, 2026
Patent 12622869
LIPID EMULSION FOR PARENTERAL ADMINISTRATION
5y 4m to grant Granted May 12, 2026
Patent 12616707
COMPOSITIONS AND METHODS FOR IMPROVING GUT HEALTH
2y 11m to grant Granted May 05, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
37%
Grant Probability
55%
With Interview (+18.0%)
4y 3m (~2m remaining)
Median Time to Grant
High
PTA Risk
Based on 791 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month